SLQT Earnings

SLQT reported its FY2026Q2 earnings on 2026-02-05, showcasing a revenue of 0.00 against an estimate of 520.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.17 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following SLQT's FY2026Q2 earnings announcement on 2026-02-05, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, SLQT's stock price tends to shift by an average of +14.36% in the 10 days leading up to earnings and -3.41% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate SLQT’s annual revenue to reach 531.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.3% and EPS estimates Revise Downward by -1.3% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SLQT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Downward by -0.3%, while EPS estimates moved Revise Downward by -1.3% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SLQT's stock price typically moves by +14.36% in the 10 days before its earnings and -3.41% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.00 and revenue of 531.00M.

The earnings call reflects several challenges: increased costs in the Life Insurance division, dependence on SelectRx amidst reimbursement headwinds, and a decline in Senior segment revenues and EBITDA. Despite revenue growth, the company faces significant short-term financial hurdles, with a negative quarterly EBITDA and declining policy production. The Q&A section reveals uncertainty in reimbursement rate improvements and vague management responses, further dampening sentiment. Without a clear positive catalyst or partnership announcement, these factors collectively suggest a negative stock price reaction in the short term.